{"id":56248,"date":"2023-04-26T16:06:23","date_gmt":"2023-04-26T14:06:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/"},"modified":"2023-04-26T16:06:23","modified_gmt":"2023-04-26T14:06:23","slug":"bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/","title":{"rendered":"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present dose expansion data from the ongoing Phase 1\/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. BCA101 is a first in class dual-action bifunctional antibody designed to inhibit EGFR and disable TGF-\u03b2 directly at the tumor site. These data will be presented in an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 2-6, 2023 in Chicago, IL.<\/p>\n

<\/a><\/p>\n

\nDetails of the oral presentations are as follows:<\/p>\n

\nTitle: <\/b>Dose expansion results of the bifunctional EGFR\/TGF-\u03b2 inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
\n
Presenter: <\/b>Glenn J. Hanna, M.D.
\n
Abstract Number: <\/b>6005
\n
Session Type\/Title: <\/b>Oral Abstract Session \u2013 Head and Neck Cancer
\n
Date\/Time: <\/b>June 5, 2023 from 8:00-11:00 a.m. CT
\n
Location: <\/b>McCormick Place Convention Center<\/p>\n

\nThis presentation described here will be made available on the Bicara website following the conference.<\/p>\n

\nAbout Bicara Therapeutics<\/b><\/p>\n

\nBicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company\u2019s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara\u2019s lead asset, BCA101, a first-in-class EGFR \/ TGF-\u03b2-trap bifunctional antibody, is currently enrolling patients in a Phase 1\/1b study. Bicara\u2019s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy. More information is available at www.bicara.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/b>
Sarah McCabe
\n
Stern Investor Relations, Inc.
\n
sarah.mccabe@sternir.com<\/a>
212-362-1200<\/p>\n

\nMedia<\/b>
Chris Railey
\n
Ten Bridge Communications
\n
chris@tenbridgecommunications.com<\/a>
617-834-0936<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present dose expansion data from the ongoing Phase 1\/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56248","6":"format-standard","7":"category-industry"},"yoast_head":"\nBicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present dose expansion data from the ongoing Phase 1\/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T14:06:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230426005625\/en\/1775264\/21\/Bicara-HorizLogo-2Color-500px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\\\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting\",\"datePublished\":\"2023-04-26T14:06:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/\"},\"wordCount\":336,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005625\\\/en\\\/1775264\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/\",\"name\":\"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\\\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005625\\\/en\\\/1775264\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\",\"datePublished\":\"2023-04-26T14:06:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005625\\\/en\\\/1775264\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005625\\\/en\\\/1775264\\\/21\\\/Bicara-HorizLogo-2Color-500px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\\\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present dose expansion data from the ongoing Phase 1\/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-26T14:06:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230426005625\/en\/1775264\/21\/Bicara-HorizLogo-2Color-500px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting","datePublished":"2023-04-26T14:06:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/"},"wordCount":336,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005625\/en\/1775264\/21\/Bicara-HorizLogo-2Color-500px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/","name":"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005625\/en\/1775264\/21\/Bicara-HorizLogo-2Color-500px.jpg","datePublished":"2023-04-26T14:06:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230426005625\/en\/1775264\/21\/Bicara-HorizLogo-2Color-500px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230426005625\/en\/1775264\/21\/Bicara-HorizLogo-2Color-500px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bicara-therapeutics-announces-oral-presentation-of-head-and-neck-cancer-dose-expansion-data-from-phase-1-1b-study-of-bca101-at-upcoming-2023-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1\/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56248"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56248\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}